Advertisement

Trophoblasttumoren

  • Ossi R. Köchli
  • Edgar Petru
  • Bernd-Uwe Sevin
Chapter

Zusammenfassung

In Mitteleuropa sind Trophoblasttumoren, insbesondere die malignen, sehr selten. Meist werden sie durch extrem hohe HCG-Werte und Metrorrhagien bzw. Abortsymptome entdeckt. Nach Diagnosestellung ist ein rasches, bildgebendes Staging notwendig, um eine Metastasierung auszuschließen oder zu bestätigen. Trophoblasttumoren sind sehr chemosensibel. Deshalb stellt die Chemotherapie die wichtigste Therapieoption dar. In der Nachsorge ist die Überwachung des β-HCG essenziell.

Literatur

  1. AGO, OEGGG und SGGG (2015) S2k Leitlinie Gestational and non-gestational trophoblastic diseaseGoogle Scholar
  2. Andrijono A, Muhilal M (2010) Prevention of post-mole malignant trophoblastic disease with vitamin A. Asian Pac J Cancer Prev 11:567–570PubMedGoogle Scholar
  3. Bagshawe K, Dent J, Webb J (1986) Hydatidiform mole in England and Wales 1973–1983. Lancet I: 673–677Google Scholar
  4. Bagshawe K, Lawler S, Paradinas F, Dent J, Brown P, Boxer G (1990) Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 335:1074CrossRefGoogle Scholar
  5. Berkowitz R, Bernstein M, Laborde O, Goldstein D (1994) Subsequent pregnancy experience in patients with gestational trophoblastic disease. J Reprod Med 39:228–232PubMedGoogle Scholar
  6. Cole L, Khanlian S, Muller C (2009) Normal production of human chorionic gonadotropin in perimenopausal and menopausal women and after oophorectomy. Int J Gynecol Cancer 19:1556–1559CrossRefGoogle Scholar
  7. Fang J, Wang S, Han X, An R, Wang W, Xue Y (2012) Role of adjuvant hysterectomy in management of high-risk gestational trophoblastic neoplasia. Int J Gynecol Cancer 22:509–514CrossRefGoogle Scholar
  8. Goto S, Ino K, Mitsui T et al (2004) Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol 93:529–535CrossRefGoogle Scholar
  9. Hoekstra A, Keh P, Lurain J (2004) Placental site trophoblastic tumor: a review of 7 cases and their implications for prognosis and treatment. J Reprod Med 49:447–452PubMedGoogle Scholar
  10. Huang M, Pinto A, Castillo R, Slomovitz M (2017) Complete serologic response to pembrolizumab in a woman with chemoresistant metastatic choriocarcinoma. J Clin Oncol 3173Google Scholar
  11. Knox S, Brooks S, Wong-You-Cheong J et al (2002) Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support. Gynecol Oncol 85:204–208CrossRefGoogle Scholar
  12. Köchli OR (1994) Staging der malignen Trophoblasterkrankungen: Ein Dilemma. Gynakol Geburtshilfe Rundsch 34:3–6CrossRefGoogle Scholar
  13. Köchli OR, Schär G, Sevin BU et al (1995) In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms. Anti Cancer Drugs 6:94–100CrossRefGoogle Scholar
  14. Kohorn EI (2001) The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assesssment. Int J Gynecol Cancer 11:73–77CrossRefGoogle Scholar
  15. Lan C, Li Y, He J, Liu J (2010) Placental site trophoblastic tumor: lymphatic spread and possible target markers. Gynecol Oncol 116:430–570CrossRefGoogle Scholar
  16. Li-Pai C, Shu-Mo C, Jian-Xuan F, Zi-Ting L (1995) PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma. Gynecol Oncol 56:231–234CrossRefGoogle Scholar
  17. Newlands E, Bagshawe K, Begent R, Rustin G, Holden L (1991) Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumors, 1979–1989. Br J Obstet Gynaecol 98:550–557CrossRefGoogle Scholar
  18. Newlands E, Mulholland P, Holden L et al (2000) Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental trophoblastic tumors. J Clin Oncol 18:854–859CrossRefGoogle Scholar
  19. Ngan H (2004) The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 14:202–205CrossRefGoogle Scholar
  20. Seckl M, Fisher R, Salerno G et al (2000) Choriocarcinoma and partial hydatidiform moles. Lancet 356:36–39CrossRefGoogle Scholar
  21. Soper J, Evans A, Rodriguez G et al (1995) Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol 56:421–424CrossRefGoogle Scholar
  22. Woolas R, Bower M, Newlands E et al (1998) Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynecol 105:1032–1035CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Ossi R. Köchli
    • 1
  • Edgar Petru
    • 2
  • Bernd-Uwe Sevin
    • 3
  1. 1.Privatklinik Zürich-BethanienGynäkologisch-onkologische Praxis BrustzentrumZürichSchweiz
  2. 2.Universitätsklinik für Frauenheilkunde und GeburtshilfeMedizinische Universität GrazGrazÖsterreich
  3. 3.Mayo Clinic FloridaPonte Vedra BeachUSA

Personalised recommendations